Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Fineline Cube Aug 21, 2026
Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Fineline Cube Aug 21, 2026
Company Drug

BrightGene Bio Receives FDA Clearance for Generic Eribulin APIs, Advancing in Breast Cancer Treatment

Fineline Cube Aug 22, 2024

BrightGene Bio-Medical Technology Co., Ltd, a Chinese pharmaceutical company listed on the Shanghai Stock Exchange...

Company

Sisram Medical Reports 2024 Interim Revenues with Growth in Key Regions and New Product Launches

Fineline Cube Aug 22, 2024

Sisram Medical Ltd (HKG: 1696), an Israel-based subsidiary of the Fosun Pharmaceutical Group, has released...

Company Drug

Daiichi Sankyo Launches Tarlige for Diabetes Peripheral Neuropathic Pain in China

Fineline Cube Aug 22, 2024

Daiichi Sankyo (TYO: 4568), a leading Japanese pharmaceutical company, has announced the official market launch...

Company Deals

Changchun GeneScience Pharmaceutical Expands Reach with HuChuang Union Partnership

Fineline Cube Aug 22, 2024

Changchun GeneScience Pharmaceutical Co., Ltd, a Chinese pharmaceutical enterprise, has established a partnership with HuChuang...

Company Deals

SynthAsia and Shanghai General Hospital Partner to Advance Diabetic Retinopathy Research

Fineline Cube Aug 22, 2024

SynthAsia has forged a strategic partnership with Shanghai General Hospital, focusing on scientific innovation within...

Company

Jiangsu Hengrui Pharmaceuticals Reports 21.78% YOY Revenue Growth and 48.67% Increase in Net Profit for H1 2024

Fineline Cube Aug 22, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd, a leading pharmaceutical company based in China with shares traded...

Drug

Akeso Biopharma’s Ivonescimab Earns Category 1 Recommendation in China’s 2024 Lung Cancer Clinical Guideline

Fineline Cube Aug 22, 2024

Akeso Biopharma, a China-based pharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 9926),...

Company Drug

Hangzhou Biosunpharma’s OB756 New Drug Application Accepted for Myelofibrosis Treatment by China’s NMPA

Fineline Cube Aug 22, 2024

Hangzhou Biosunpharma Co., Ltd. has announced that the National Medical Products Administration (NMPA) has accepted...

Company

R&D Investments and Operating Cash Flows Highlight Resilience in Simcere Pharma’s H1 2024 Financial Report

Fineline Cube Aug 22, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has reported its financial results for the first...

Company Policy / Regulatory

US Congressmen Call for FDA Investigation into Clinical Trials at China’s Military Hospitals

Fineline Cube Aug 22, 2024

US lawmakers are intensifying their scrutiny of the involvement of Chinese military hospitals in hosting...

Company Drug

Jiangsu Hansoh and GSK Receive FDA Breakthrough Designation for B7-H3 Targeted ADC in Small-Cell Lung Cancer

Fineline Cube Aug 22, 2024

Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692), a prominent Chinese pharmaceutical company, and its UK...

Company Deals

Henlius Biotech Secures Exclusive Rights to Commercialize Convalife’s Generic Neratinib in China and Abroad

Fineline Cube Aug 22, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has entered...

Company

WuXi XDC Reports 67.6% YOY Revenue Growth and Expands Manufacturing with Singapore Plant

Fineline Cube Aug 22, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Deals Medical Device

Bone Index Secures Financing to Expand Manufacturing and Promote Diagnostic Technology Globally

Fineline Cube Aug 22, 2024

Bone Index, a Finland-based medical technology company specializing in bone diagnostics, has announced the successful...

Company

Chengdu Kanghua Biological Products Reports 16.81% YOY Revenue Growth in H1 2024 Financial Results

Fineline Cube Aug 22, 2024

Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has...

Company Drug

J&J’s Rybrevant-Lazclude Combo Approved by FDA, Challenging AstraZeneca’s Tagrisso in NSCLC Treatment

Fineline Cube Aug 22, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has secured a new market approval in the United...

Company

CSPC Pharmaceutical Group Reports Moderate H1 2024 Revenue Growth with Patent Medicines Driving the Increase

Fineline Cube Aug 22, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading China-based pharmaceutical enterprise, has announced its financial...

Company Drug

AstraZeneca’s Strensiq Approved for Rare Disease Therapy under Greater Bay Area’s Drug Access Policy

Fineline Cube Aug 22, 2024

AstraZeneca (NASDAQ: AZN, LON: AZN) , a leading UK pharmaceutical company, has received approval for...

Company Deals

Johnson & Johnson to Acquire Israeli Cardiovascular Device Maker V-Wave for Upfront USD 600 Million

Fineline Cube Aug 22, 2024

Johnson & Johnson (NYSE: JNJ), a multinational healthcare conglomerate based in the US, has announced...

Policy / Regulatory

China’s VBP Office Exposes Collusion Among Six Firms in Bromhexine Bidding Process

Fineline Cube Aug 22, 2024

The National Drug Alliance Procurement Office, which oversees the Volume-Based Procurement (VBP) program, has issued...

Posts pagination

1 … 355 356 357 … 711

Recent updates

  • METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines
  • CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors
  • LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval
  • China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect
  • Boehringer Ingelheim Upgrades China Strategy with New Shanghai R&D Center, Deepening Investment in Pharma and Animal Health
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.